N/A N=185 A Novel Transition Program to Reduce Disability After Stroke
Ischemic Stroke · Hemorrhagic Stroke
Primary: Reintegration to Normal Living Index (RNLI) — 60.8; 61.2; 74.8; 73.9 score on a scale — p=0.76
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=21 Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
Prostate Cancer Recurrent · Prostate Cancer · Prostate Adenocarcinoma
Primary: Number of Participants With Dose-limiting Toxicities (Treatment-related Adverse Events) as Assessed by the CTCAE v5.0 — 0; 0; 0 Participants
Phase 3 N=174 Phase III Study (Tarceva®) vs Chemotherapy to Treat Advanced Non-Small Cell Lung Cancer in Patients With Mutations in the TK Domain of EGFR
Non-Small Cell Lung Cancer
Primary: Progression Free-survival — 9.4; 5.2 months — p=0.0001
N/A N=4,080 Patient-Clinic-Community Integration to Prevent Obesity Among Rural Preschool Children
Pediatric Obesity · Preventive Medicine · Mentoring
Primary: Difference in BMI Z-score, Based on WHO Growth Standards — 1.005; 0.881; 0.979 BMI z-score
N/A N=571 A Skills-based RCT for Physical Activity Using Peer Mentors
Health Behavior · Obesity · Motor Activity
Primary: Change in Body Mass Index From T1 to T3 — -.9257; -.6503 kg/m2
Phase 2 N=22 Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis
Ulcerative Colitis
Primary: Number of Treatment-emergent Adverse Events — 145 events
N/A N=33 Noninvasive Brain Stimulation in Mild Cognitive Impairment and Dementia
Alzheimer Disease · Mild Cognitive Impairment · Dementia
Primary: Change in Score on the Rey Auditory Verbal Learning Test (RAVLT) — 13.8; 17.8; 18.0; 13.4 T-score on a scale — p=0.25
N/A N=385 Virtual Reality Therapy for Chronic Low Back Pain
Chronic Low Back Pain
Primary: Change From Baseline in Patient-Reported Outcomes Measurement Information System Pain Interference (PROMIS-PI) at Day 30 — -1.15; -1.86; -1.67 units on a scale — p=0.4884
Phase 4 N=96 Dosage of Epidural Morphine in Elderly Patients
Age Problem · Abdominal Cancer
Primary: Total Patient-controlled Analgesia (PCA) Morphine Sulphate (MS) Consumption. — 27.182; 9.182; 6.273; 38.136 mg
Phase 2 N=60 Imaging Inflammation in Alzheimer's Disease
Alzheimer's Disease
Primary: 11C-PBR28 Binding — 1.25; 1.15; 1.16; 1.02 SUVR
Phase 2 N=13 A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
AL Amyloidosis
Primary: Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) and Adverse Events (AEs), and AEs Leading to Treatment Discontinuation — 4; 3; 6; 13…
Phase 1 N=15 An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
Kaposi Sarcoma · HIV Infections
Primary: To Determine the Safety of Escalating Doses of Tc 99m Tilmanocept in HIV Subjects With Biopsy-confirmed KS. — 0; 0; 0 Safety Signals
N/A N=50 Threat Interpretation Bias as Cognitive Marker and Treatment Target in Pediatric Anxiety
Anxiety Disorders
Primary: Change in Linguistic Interpretation Bias as Assessed by the Word-sentence Association Paradigm for Youth (WSAP-Y) — 19.77; 47.40 score on a scale
Phase 2 N=119 Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
Atopic Dermatitis Eczema
Primary: Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8 — -43.5; -62.0 Percent change from baseline
Phase 2 N=61 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
Smoldering Multiple Myeloma
Primary: Proportion Of High Risk SMM Patients Who Are Progression Free 2 Years After Receiving IRD Combination Therapy — 50 Participants